These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 23858038)

  • 1. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
    Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
    Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer.
    Muto S; Nakajima A; Horiuchi A; Inoue M; China T; Saito K; Isotani S; Hisasue S; Yamaguchi R; Ide H; Horie S
    Jpn J Clin Oncol; 2013 Mar; 43(3):305-13. PubMed ID: 23303841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
    Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial.
    Kanagawa Urological Research Group (KURG)
    Jpn J Clin Oncol; 2012 Sep; 42(9):813-9. PubMed ID: 22761255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
    Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
    J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
    Herr HW
    J Urol; 2012 Feb; 187(2):435-7. PubMed ID: 22177154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Mostafid H
    Int J Urol; 2010 Sep; 17(9):766-7. PubMed ID: 20727047
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
    Pfister C; Kerkeni W; Rigaud J; Le Gal S; Saint F; Colombel M; Guy L; Wallerand H; Irani J; Soulie M;
    Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
    Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
    Ooi WL; Stockler M; Hayne D
    Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.